Dear Editor
May I add this to my previous response, please. Although I know of the work, I have just seen the actual paper.
It is the work of Dr Tarek Alam and five colleagues, using ivermectin and doxycycline.
Just one quote:
“Result:
This observational study, consisting of 64 males and 36 females was conducted from April to May 2020 (Figure 2) in Bangladesh Medical College. The oldest patient was 84 years and the youngest one was 8 years with most patients between the ages of 21 to 40 years (Figure 3). Patients were divided in 3 groups: Mild (73), Moderate (20) and Severe (7), based on their symptoms. From the severe patients, three had fever more than 103 Fahrenheit for seven days with severe cough and lung infiltrates , three had severe loose motion and one had uncontrolled diabetes. Out of the rest, 20 patients had moderate symptoms of mild fever (100 Fahrenheit) and mild cough. Moreover, 73 had mild symptoms of malaise, sore throat, loss of smell, loss of taste, and body ache. Fifty percent symptomatic improvement of mild to moderate patients was seen between 3rd to 5th day after starting treatment. All 7 severe patients’ symptoms subsided by 50 percent by 7th day of treatment. Retesting was done between 4 to 18 days of starting medication (Figure 4). Twenty five patients underwent retesting between 4th to 8th days, 51 between 9th to 13th days and 24 between 14th to 18th days from starting medication. All of the patients tested negative. None needed intensive care admission and no deaths were reported.”
Rapid Response:
Re: The BMJ interview: Anthony Fauci on covid-19
Dear Editor
May I add this to my previous response, please. Although I know of the work, I have just seen the actual paper.
It is the work of Dr Tarek Alam and five colleagues, using ivermectin and doxycycline.
http://www.bcpsjournal.org/mhcms-admin/media/pdf/article762.pdf
Just one quote:
“Result:
This observational study, consisting of 64 males and 36 females was conducted from April to May 2020 (Figure 2) in Bangladesh Medical College. The oldest patient was 84 years and the youngest one was 8 years with most patients between the ages of 21 to 40 years (Figure 3). Patients were divided in 3 groups: Mild (73), Moderate (20) and Severe (7), based on their symptoms. From the severe patients, three had fever more than 103 Fahrenheit for seven days with severe cough and lung infiltrates , three had severe loose motion and one had uncontrolled diabetes. Out of the rest, 20 patients had moderate symptoms of mild fever (100 Fahrenheit) and mild cough. Moreover, 73 had mild symptoms of malaise, sore throat, loss of smell, loss of taste, and body ache. Fifty percent symptomatic improvement of mild to moderate patients was seen between 3rd to 5th day after starting treatment. All 7 severe patients’ symptoms subsided by 50 percent by 7th day of treatment. Retesting was done between 4 to 18 days of starting medication (Figure 4). Twenty five patients underwent retesting between 4th to 8th days, 51 between 9th to 13th days and 24 between 14th to 18th days from starting medication. All of the patients tested negative. None needed intensive care admission and no deaths were reported.”
Competing interests: No competing interests